Transgenomic Posts 22 Percent Decline in PGx Business, but Predicts Segment 'Swell' in Coming Months | GenomeWeb

By Turna Ray

Although Transgenomic reported a 22 percent drop in revenues for its pharmacogenomics services business in the first quarter of 2011, company officials believe that segment of its business will contribute significantly to earnings in the coming months as a number of newly signed genomic testing arrangements with pharmaceutical companies start to bring in money.

Transgenomic reported a 39 percent increase in overall sales to $7.5 million from $5.4 million in the first quarter of 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.